Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07806045 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Nebulized UC-EVs for Recurrent or Refractory IMIDs With Lung Involvement

Name: Nebulized UC-EVs for Recurrent or Refractory IMIDs With Lung Involvement — clinical trial record (NCT07806045)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhaseEarly Phase 1

SponsorQiubai Li

Started2026-10-14

View on ClinicalTrials.gov ↗

Qiubai Li

2 trials monitored

See all monitored trials

Scleroderma

302 trials monitored

See 9 trials at risk

Immune-mediated inflammatory diseases (IMIDs) are systemic inflammatory disorders driven by dysregulated immune responses that can affect multiple organs, including the lungs. Examples include Behçet disease, IgG4-related disease, and systemic sclerosis (SSc). IMID-related lung involvement may cause progressive lung damage, impaired lung function, disability, and increased mortality, but effective targeted treatment options remain limited. This clinical trial will study nebulized human umbilical cord mesenchymal stromal cell-derived extracellular vesicles, also called UC-EVs, in adults with recurrent or refractory IMIDs with lung involvement.

Trial Details

NCT Number	NCT07806045
Lead Sponsor	Qiubai Li Collaborators: Peking Union Medical College Hospital, Shandong Qilu Stem Cells Engineering Co., Ltd.
Conditions	IgG4 Related Disease, Systemic Sclerosis (SSc)
Enrollment	18 participants
Start Date	2026-10-14
Primary Completion	2028-07-30 (estimated)
Study Completion	2029-07-30 (estimated)
Updated on ClinicalTrials.gov	2026-09-08